Safely & Securely Harness AI to Diagnose & Optimize Treatment Outcomes for Dry AMD
Tracery Ophthalmics empowers ophthalmologists with a cross-modal image analytics solution geared specifically to dry Age Related Macular Degeneration.
​
Whether slowing AMD progression, reducing the onset and evolution of incomplete GA, or reducing GA expansion over time, Tracery supports clinical decision making by safely and seamlessly deploying dedicated ML/AI algorithms to identify and quantify known and novel imaging biomarkers.
We make the complex,
simple.
THE CHALLENGE
As 1st generation, 1st ever treatments for dry AMD emerge, eye care practitioners need to rapidly and accurately identify patients well-suited to therapy, while excluding those who are not
TRACERY'S SOLUTION
At Tracery, we simplify image analysis by using computer vision to identify AMD risk factors
THE CHALLENGE
As next generation treatments emerge, pharma and eye care practitioners will need to rapidly and accurately distinguish patients that are well suited to treatment and prevention strategies
TRACERY'S SOLUTION
XXX
THE CHALLENGE
As treatments for dry AMD evolve, payers will need to see benefit to society in terms of quality of life and cost
TRACERY'S SOLUTION
XXX